Stride.Start →

The evidence base behind modern GLP-1 weight management is unusually strong — multiple large, randomized, placebo-controlled trials published in top journals, with cardiovascular outcome data. This guide summarizes the landmark studies you (or your doctor) might reference. Use it for context, source-verification, or simply to understand the depth of what's been proven.

All studies cited are peer-reviewed and publicly accessible via PubMed. Citations follow each entry.

STEP — the trials that established Wegovy

The Semaglutide Treatment Effect in People with Obesity (STEP) programme produced the foundational evidence for Wegovy (semaglutide 2.4 mg) in chronic weight management.

STEP 1 — adults with obesity, no diabetes

  • Design: RCT, 1,961 adults with BMI ≥30 (or ≥27 with comorbidity), no diabetes. 68 weeks. Semaglutide 2.4 mg/week vs placebo, both with lifestyle intervention.
  • Primary outcome: mean body weight change at week 68.
  • Result: -14.9% (semaglutide) vs -2.4% (placebo). 86% of semaglutide patients lost ≥5%; 69% lost ≥10%; 50.5% lost ≥15%.
  • Citation: Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002. PubMed

STEP 2 — adults with obesity + type 2 diabetes

  • Design: RCT in 1,210 adults with T2D + BMI ≥27. 68 weeks.
  • Result: Semaglutide 2.4 mg → -9.6% weight loss + HbA1c reduction of 1.6%.
  • Citation: Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes. Lancet 2021;397:971-984. PubMed

STEP 3 — semaglutide + intensive behavioural therapy

  • Result: -16% weight loss with combined intervention.
  • Citation: Wadden TA et al. JAMA 2021;325:1403-1413. PubMed

STEP 4 — what happens when you stop

  • Design: Patients who'd lost weight over 20 weeks on semaglutide were randomized to continue or switch to placebo for 48 more weeks.
  • Result: Continuers maintained loss. Switchers regained 2/3 of the loss within a year.
  • Implication: GLP-1 is most effective as a continuous, chronic-condition treatment.
  • Citation: Rubino D et al. JAMA 2021;325:1414-1425. PubMed

STEP 5 — long-term (2 years)

  • Result: -15.2% weight loss sustained over 104 weeks on semaglutide.
  • Citation: Garvey WT et al. Nat Med 2022;28:2083-2091. PubMed

STEP 8 — semaglutide vs liraglutide (head-to-head)

  • Result: Semaglutide 2.4 mg produced 3× more weight loss than daily liraglutide 3.0 mg (-15.8% vs -6.4%).
  • Citation: Rubino DM et al. JAMA 2022;327:138-150. PubMed

SURMOUNT — the trials that established Mounjaro

The SURMOUNT programme established tirzepatide (Mounjaro/Zepbound) as the most-effective injectable for weight management to date.

SURMOUNT-1 — adults with obesity, no diabetes

  • Design: RCT, 2,539 adults with BMI ≥30 (or ≥27 with comorbidity), no diabetes. 72 weeks. Tirzepatide 5, 10, or 15 mg vs placebo.
  • Result: Mean weight reduction of -15.0%, -19.5%, and -20.9% for tirzepatide 5, 10, and 15 mg, vs -3.1% placebo. 57% of patients on 15 mg lost ≥20%.
  • Citation: Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216. PubMed

SURMOUNT-2 — adults with T2D

  • Result: Tirzepatide 15 mg → -14.7% in T2D patients (typically harder to lose weight).
  • Citation: Garvey WT et al. Lancet 2023;402:613-626. PubMed

SURMOUNT-3 — tirzepatide as maintenance after lifestyle-driven loss

  • Result: Patients who'd lost 6.9% on lifestyle then added tirzepatide lost an additional 18.4% over 72 weeks. Placebo group regained 2.1%.
  • Citation: Wadden TA et al. Nat Med 2023;29:2909-2918. PubMed

SURMOUNT-4 — what happens when you stop tirzepatide

  • Design: Open-label tirzepatide for 36 weeks, then randomized to continue or switch to placebo for 52 weeks.
  • Result: Continuers lost additional weight (cumulative -25.3%); switchers regained most (cumulative -9.9%).
  • Citation: Aronne LJ et al. JAMA 2024;331:38-48. PubMed

SELECT — the cardiovascular outcome trial

The single most-important trial in the GLP-1 weight management space for cardiologists and longevity.

  • Design: RCT, 17,604 adults with BMI ≥27 + established cardiovascular disease (prior MI, stroke, or PAD), without diabetes. Semaglutide 2.4 mg vs placebo. Mean follow-up 3.3 years.
  • Primary outcome: composite MACE (cardiovascular death, non-fatal MI, non-fatal stroke).
  • Result: 20% relative risk reduction in MACE (HR 0.80, 95% CI 0.72-0.90, p<0.001). Significant reductions in non-fatal MI individually.
  • Implication: GLP-1-driven weight loss directly prevents heart attacks and strokes, independent of diabetes status. Established cardiovascular indication for semaglutide.
  • Citation: Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232. PubMed

SUSTAIN — the diabetes outcome programme for semaglutide

Established semaglutide's safety and cardiovascular profile in type 2 diabetes — predecessor to SELECT.

SUSTAIN-6

  • Design: 3,297 patients with T2D + high CV risk. Semaglutide vs placebo, 104 weeks.
  • Result: 26% reduction in MACE. First semaglutide cardiovascular outcome trial.
  • Citation: Marso SP et al. NEJM 2016;375:1834-1844. PubMed

SCALE — the trials for liraglutide (Saxenda)

The predecessor GLP-1 for chronic weight management.

SCALE Obesity and Prediabetes

  • Result: Liraglutide 3.0 mg → -8.4% weight loss over 56 weeks.
  • Citation: Pi-Sunyer X et al. NEJM 2015;373:11-22. PubMed

SCALE Sleep Apnea

  • Result: Liraglutide-driven weight loss produced clinically meaningful improvement in obstructive sleep apnoea (AHI reduction).
  • Citation: Blackman A et al. Int J Obes 2016;40:1310-1319. PubMed

DPP — the foundational diabetes prevention trial

Pre-GLP-1 evidence that even modest sustained weight loss prevents type 2 diabetes.

  • Design: 3,234 adults with pre-diabetes. Lifestyle intervention (target 7% weight loss + 150 min/week activity) vs metformin vs placebo.
  • Result: Lifestyle reduced 3-year incidence of T2D by 58%. Metformin by 31%.
  • Citation: Knowler WC et al. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. NEJM 2002;346:393-403. PubMed

Look AHEAD — long-term lifestyle weight loss

  • Design: 5,145 adults with T2D + overweight/obesity. Intensive lifestyle intervention vs standard diabetes support. 9.6 years follow-up.
  • Result: Intensive arm lost more weight, had better fitness, but did NOT have lower cardiovascular events vs control (the trial was stopped early on futility).
  • Implication: Lifestyle alone, in this trial population, did not translate weight loss into hard CV outcomes — providing some of the rationale for medication-augmented programs.
  • Citation: The Look AHEAD Research Group. NEJM 2013;369:145-154. PubMed

SOS — long-term bariatric surgery outcomes

The longest-running data on durable weight loss outcomes.

  • Design: Prospective non-randomized cohort. ~4,000 patients with bariatric surgery vs matched non-surgical controls. Follow-up 20+ years.
  • Result: Surgery → sustained 25% weight loss; 23% reduction in all-cause mortality; 30% reduction in CV mortality; ~25% reduction in cancer mortality in women.
  • Citation: Sjöström L et al. Bariatric Surgery and Long-term Cardiovascular Events. JAMA 2012;307:56-65. PubMed

SCALE-IBT / STEP-3 — weight loss + behavioural therapy

Demonstrated that combining GLP-1 with intensive behavioural therapy increases outcomes beyond medication alone (-16% vs -5.7% placebo + IBT).

  • Citation: Wadden TA et al. JAMA 2021;325:1403-1413.

What this evidence base tells you

  1. Wegovy → ~15% average weight loss over 68 weeks (STEP-1)
  2. Mounjaro 15 mg → ~21% average weight loss over 72 weeks (SURMOUNT-1)
  3. Stopping abruptly → most weight regained within a year (STEP-4, SURMOUNT-4)
  4. Semaglutide reduces cardiovascular events by 20% independent of diabetes (SELECT)
  5. Even modest sustained loss (7%) reduces type 2 diabetes incidence by 58% (DPP)
  6. Bariatric surgery (25% sustained loss) reduces all-cause mortality by 23% over 20 years (SOS)

For India-specific clinical considerations (lower BMI cutoffs for South Asian patients, central adiposity patterns), these trial outcomes are directionally applicable, with the Indian adult population often deriving similar or greater metabolic benefit from a given % weight loss.

How Stride uses this evidence

Stride's clinical protocols are built around current evidence:

  • GLP-1 selection follows the STEP, SURMOUNT, SUSTAIN, and SELECT outcomes
  • Dose titration follows the manufacturer protocols validated in these trials
  • Continuous monitoring reflects STEP-4 and SURMOUNT-4 findings on discontinuation
  • 3-month program structure with reassessment reflects clinical practice for chronic-condition management

Frequently asked questions

Are these studies applicable to Indian patients? The trials enrolled multi-ethnic populations, including South Asian participants. Indian-specific real-world evidence is growing but generally aligns with trial outcomes. Indian clinical guidelines (RSSDI, AAPI) reference these studies.

Where can I read the full papers? All cited papers are indexed on PubMed (pubmed.ncbi.nlm.nih.gov) — most abstracts are free; many full texts are accessible via the journal or institutional access.

Are there longer-term safety studies? Yes — semaglutide and tirzepatide have multi-year follow-up data showing no new safety signals beyond those identified in initial trials. Long-term cardiovascular benefit was confirmed in SELECT (3.3-year follow-up).

What about Indian-led studies? A growing body of Indian real-world evidence has been published on Ozempic and Wegovy use in Indian patients (RSSDI publications, AAPI conference proceedings). Direct head-to-head Indian RCTs are still emerging.

Are there any negative findings? The SELECT and SURMOUNT trials found no new safety signals beyond expected GI side effects. Pancreatitis incidence was numerically slightly higher in active arms but not statistically different from placebo. Long-term thyroid surveillance continues.

Further reading

Ready to start with an evidence-based program?

Check your eligibility — Stride's clinicians prescribe based on the trial evidence summarized above.

Clinical research setting
Clinical research setting
Medical injection — the focus of multiple landmark GLP-1 trials
Medical injection — the focus of multiple landmark GLP-1 trials
Ready when you are

Doctor-led, continuously monitored.

3-Month Early Edition: ₹9,999 (regular ₹23,999). One-time payment, no auto-renewal.

Check Your Eligibility →